Global Non-Small Cell Lung cancer Market Research and Forecast 2022-2028

Description

List of Tables

Global Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report By Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others), By Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Cryosurgery, and Others). By Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), By End-User (Multispecialty Hospitals and Cancer Research Centers) Forecast, 2021-2027

The global non-small cell lung cancer market is growing at a CAGR of 9.6% during the forecast period (2021-2027). NSCLC is a type of cancer that is most common among smokers as well as non-smokers group of people. NSCLC in comparison to the other form of cancer called small cell lung cancer grows and spreads less aggressively. Therefore, NSCLC has a better chance of treatment with surgery, chemotherapy, and other medical treatments. The major factor propelling the growth of the NSCLC market includes evolving drug landscape for the treatment of NSCLC. The major factors that are augmenting the growth of the market are the rise in air pollution, smoking cigarettes, pipes, or cigars, being in exposure to asbestos, arsenic, chromium, beryllium, nickel, soot, or tar in the workplace, and being exposed to radiation. Around 84% of the tumor is non-small cell lung cancer and most of the advanced stage is treated with chemotherapy, targeted drugs, and/or immunotherapy.

In addition to this, hereditary causes and being infected with HIV are another factor that drives the global non-small cell lung cancer diagnostics and therapeutics market. However, the high cost of drugs and treatment and the risk associated with it are some of the restraints that can challenge the growth of the market in the forecast period. Conversely rise in better chances of treatment with surgery, chemotherapy, and other medical treatments are estimated to be the opportunity for the market players. Moreover, the significant increase in the R&D activities supported by government organizations such as the American Lung Association, which has made support for lung cancer research its top priority, is also aiding with the growth of the market.

Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market

The global non-small lung cancer market is hardly hit by the COVID-19 pandemic since December 2019. Key industry therapy of non-small cell lung cancer includes chemotherapy, radiation therapy, surgery, and targeted therapy in top economies such as China, the US, and European Union. The COVID-19 pandemic in these major economies has led to delay in treatment across the globe. Moreover, the frequent visits to hospitals might considerably increase the risk of being infected due to which many patients themselves decided to delay the treatment. During the global pandemic, the 30-day mortality rate in patients with newly diagnosed NSCLC significantly increased with the pandemic from 25% before COVID-19 to 49% during COVID-19. However, the market will witness "W" shape recovery in near future owing to the increase in the number of patients who experienced a delay in treatment in major economies. The market will show a decline in share twice due to the most economies faced by the second wave. One of the growth opportunities includes the clinical guideline published by the National Institute for Health and Care Excellence (NICE) for the guidance of standard anticancer treatments to cancer patients with COVID-19 and to maximize the use of the available resources to sustain health services.

Segmental Outlook

The market is segmented based on type, therapy, diagnosis, and end-user. Based on the type segment, the market is segmented into adenocarcinomas, squamous cell carcinoma, large cell carcinomas, and others. Based on the therapy segment, the market is segmented into chemotherapy, targeted therapy, radiation therapy, surgery, cryosurgery, and others. Among these, the chemotherapy segment is anticipated to have significantly large shares during the forecast period. Based on the diagnosis segment, the market is segmented into CT scan, x-rays, sputum cytology, bronchoscopy, laboratory tests, thoracoscopy, and others. Further based on the end-user segment, the market is bifurcated into multispecialty hospitals and cancer research centers.

Global Non-Small Cell Lung Cancer Market Share by Type, 2020 (%)

Global Non-Small Cell Lung Cancer Market Share by Type

Adenocarcinomas segment to hold Lucrative Share in the Global NSCLC Market

The Adenocarcinomas segment hold a significant market share in 2020. According to the analysis of the LUNGevity Foundation, lung adenocarcinoma accounts for 40% of all lung cancers and is found mostly in women. Moreover, people aging between 20-46 who have lung cancer are more likely to have lung adenocarcinoma than other lung cancers. Even taking the population of people who had never smoked, most of the lung cancer was adenocarcinomas. Some of the major companies that operate in this segment include Merck & Co., Inc., DAIICHI SANKYO CO. LTD., AstraZeneca, and Bristol Myers Squibb. For instance, in April 2021, FDA approved nivolumab manufactured by Bristol-Myers Squibb for esophageal adenocarcinoma. Moreover, in January 2021, Daiichi Sankyo received approval from FDA for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.

Regional Outlooks

The global NSCLC market is analyzed based on the geographical regions that are contributing significantly to the growth of the market. Based on the geography, the market is bifurcated into North America (the US and Canada), Europe (Germany, Spain, Italy, France, the UK, and the Rest of Europe), Asia-Pacific (India, China, Japan South Korea, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East and Africa, and Latin America). North America is estimated to have the major share in the non-small cell lung cancer market. High investment by the market players, the large pool of patients, improved healthcare infrastructure, and increased government funding is some of the major factors that contribute to the share of the market. According to the American Society of Clinical Oncology's (ASCO) report published in 2020, NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnosed.

Global Non-Small Cell Lung Cancer Market Growth, by Region 2020-2026

Global Non-Small Cell Lung Cancer Market Growth, by Region

Asia-Pacific is projected to highest Contributor to the growth of the Global NSCLC market

Asia-Pacific is estimated to be one of the fastest-growing regions owing to the increase in the prevalence of lung cancer with an increase in population and less stringent government regulations. For instance, in 2020, a Phase 4, open-label, single-arm, multi-center, prospective clinical trial of dacomitinib started in India which is estimated to complete by the end of 2022. Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic NSCLC.

Market Players Outlook

Key players of the non-small cell lung cancer market include Eli Lilly and Co., Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AstraZeneca PLC, Novartis AG, and Bristol Myers Squibb Co., among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to thrive in a competitive environment. For instance, in January 2020, Merck completed the acquisition of ArQule at a purchase price of $20.00 per share. Moreover, in November 2019, Bristol-Myers Squibb Completed the acquisition of one of the leading biopharma company Celgene.

The Report Covers

Market value data analysis of 2019 and forecast to 2026.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global non-small cell lung cancer market based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Product Code: OMR2017206

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market Industry
Recovery Scenario of Global Non-Small Cell Lung Cancer Market Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on key players

4. Market Determinants

4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation

5.1. Global Non-Small Cell Lung Cancer Market By Type
- 5.1.1. Adenocarcinomas
- 5.1.2. Squamous Cell Carcinoma
- 5.1.3. Large Cell Carcinomas
- 5.1.4. Others
5.2. Global Non-Small Cell Lung Cancer Market By Therapy
- 5.2.1. Chemotherapy
- 5.2.2. Targeted Therapy
- 5.2.3. Radiation Therapy
- 5.2.4. Surgery
- 5.2.5. Cryosurgery
- 5.2.6. Others
5.3. Global Non-Small Cell Lung Cancer Market By Diagnosis
- 5.3.1. CT Scan
- 5.3.2. X-Rays
- 5.3.3. Sputum Cytology
- 5.3.4. Bronchoscopy
- 5.3.5. Laboratory Tests
- 5.3.6. Thoracoscopy
- 5.3.7. Others
5.4. Global Non-Small Cell Lung Cancer Diagnosis And Therapeutics Market By End-User
- 5.4.1. Multispeciality Hospitals
- 5.4.2. Cancer Research Centers

6. Regional Analysis

6.1. North America
- 6.1.1. United States
- 6.1.2. Canada
6.2. Europe
- 6.2.1. UK
- 6.2.2. Germany
- 6.2.3. Italy
- 6.2.4. Spain
- 6.2.5. France
- 6.2.6. Rest of Europe
6.3. Asia-Pacific
- 6.3.1. China
- 6.3.2. India
- 6.3.3. Japan
- 6.3.4. South Korea
- 6.3.5. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles

7.1. AbbVie Inc.
7.2. Agena Bioscience, Inc.
7.3. Arqule Inc.
7.4. Amgen Inc.
7.5. AstraZeneca PLC
7.6. Bayer AG
7.7. Biodesix, Inc.
7.8. Boehringer Ingelheim International GmbH
7.9. Bristol Myers Squibb Co.
7.10. DAIICHI SANKYO CO. LTD.
7.11. Eli Lilly and Co.
7.12. Exosome Diagnostics Corp.
7.13. F. Hoffman-La Roche, Inc.
7.14. Genentech, Inc.
7.15. GlaxoSmithKline PLC
7.16. Illumina, Inc.
7.17. Merck & Co., Inc.
7.18. Novartis International Ag
7.19. Personal Genome Diagnostics Inc.
7.20. Pfizer Inc.
7.21. Qiagen NV
7.22. Sanofi SA
7.23. SAGA Diagnostics AB
7.24. Thermo Fisher Scientific Inc.